- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03891784
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
Study Overview
Status
Conditions
- Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
- Metastatic Digestive System Neuroendocrine Neoplasm
- Pancreatic Neuroendocrine Tumor
- Advanced Digestive System Neuroendocrine Neoplasm
- Digestive System Neuroendocrine Tumor
- Foregut Neuroendocrine Tumor
- Hindgut Neuroendocrine Tumor
- Midgut Neuroendocrine Tumor
- Refractory Digestive System Neuroendocrine Neoplasm
Intervention / Treatment
Detailed Description
Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 4 months for up to 1 year.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: David B. Zhen
- Phone Number: 206-606-1733
- Email: dbzhen@uw.edu
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80217
- Not yet recruiting
- University of Colorado
-
Contact:
- Stephen Leong
- Phone Number: 303-724-3837
-
Principal Investigator:
- Stephen Leong
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Fred Hutch/University of Washington Cancer Consortium
-
Contact:
- David B. Zhen
- Phone Number: 206-606-1733
- Email: dbzhen@uw.edu
-
Principal Investigator:
- David B. Zhen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histologically confirmed GEP NET, radiographically progressed on at least one line of standard therapy within the past 12 months
- Primary tumors may be in: pancreas, foregut (esophagus, stomach, duodenum), midgut (small intestine, appendix), hindgut (large intestine, rectum), or unknown origin
- Tumors may be functional (associated with clinical symptoms of hormone secretion) or non-functional
- Well-differentiated NET with low grade (Ki67 index < 3% or mitotic index < 2 mitoses/10 high power field [HPF]), intermediate grade (Ki67 index 3-20% or mitotic index 2-20 mitoses/10 HPF), or high grade (Ki67 21% to ≤ 55% of mitotic index 21-55% mitoses/10 HPF). In cases where pathology reports call out only a "high grade neuroendocrine carcinoma", such patients are eligible only if well differentiated status is confirmed by a board-certified pathologist AND Ki-67 is ≤ 55%
- Metastatic or locally advanced unresectable disease
- Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
- Prior or concurrent therapy with somatostatin analogs (SSAs) is allowed. If concurrent therapy, dose must be stable for at least 2 months
Patients with carcinoid syndrome must have symptoms controlled with stable doses of SSAs for at least 2 months
* Telotristat is not allowed
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Able to swallow oral medications
- Absolute neutrophil count >= 1500/uL
- Platelet count >= 100,000/uL (without platelet transfusion for at least two weeks)
- Hemoglobin >= 8 g/dL (blood transfusion is not allowed the day before or on the day of study treatment)
- Total bilirubin =< 1.5 times upper limit of normal (ULN)
- Transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) =< 3 x upper limit of normal (ULN) (=< 5 x ULN if liver metastases)
- Patients with Gilbert's syndrome with a total bilirubin =< 2.0 times ULN and direct bilirubin within normal limits are permitted
- International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN
- Creatinine > 30 mL/min
- Ability to understand and sign the consent form
Women of child-bearing potential must:
- Have a negative serum pregnancy test within 7 days prior to initiation of treatment, and
- Agree to use a highly effective method of contraception during the study and for at least 3 weeks following the last dose of study drug
- Men must be sterile or agree to use a highly effective method of contraception during the study and for at least 3 weeks following the last dose of study drug
Exclusion Criteria:
- Presence of poorly differentiated neuroendocrine carcinoma (NEC) or mixed adenoneuroendocrine carcinomas (MANECs)
- Prior treatment with abemaciclib or other CDK4/6 inhibitors
- Known hypersensitivity to abemaciclib or its components
- Receipt of any therapy or investigational agent within 4 weeks prior to study registration, except SSAs
- Any surgery, radiation, or embolization within 4 weeks
- Peptide receptor radionuclide therapy (PRRT) within 6 weeks
- Patients receiving other investigational agents
- Patients who have not recovered from adverse events of prior therapy to =< grade 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5), except for alopecia or grade =< 2 peripheral neuropathy prior to study treatment initiation. Subjects must have fully recovered from the acute effects of any prior radiotherapy
- Patients with untreated or symptomatic brain metastases (must be off corticosteroids for >= 4 weeks)
- Uncontrolled or untreated intercurrent illness including, but not limited to, active bacterial or fungal infection, congestive heart failure, severe/unstable angina, syncope of cardiac etiology, ventricular arrythmia (including but not limited to ventricular tachycardia, ventricular fibrillation), history of cardiac arrest, interstitial lung disease, severe dyspnea at rest or requiring oxygen supplementation, arterial or venous thrombotic event, pre-existing chronic condition resulting in baseline grade >= 2 diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements
- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures involving stomach or small bowel in the last 28 days, active peptic ulcer disease, Crohn's disease or ulcerative colitis
- Severe renal impairment (e.g. estimated creatinine clearance < 30ml/min)
- Known history of infection with human immunodeficiency virus (HIV)
- Active untreated infection with hepatitis B virus (i.e. hepatitis B surface antigen positive) or hepatitis C virus (i.e. hepatitis C antibody and ribonucleic acid [RNA] positive)
- Other malignancy diagnosed or recurrent in the past 3 years (except non-melanoma skin cancer and in-situ cervical cancer)
- Pregnancy or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (abemaciclib)
Patients receive abemaciclib PO BID on days 1-28.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 1 year
|
ORR defined as complete or partial response as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, will be represented by a waterfall plot.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: From study registration to radiographic progression per RECIST v1.1 (investigator assessment), clinical progression, or death of any cause, assessed up to 1 year
|
The distribution for survival times will be estimated using the method of Kaplan-Meier; associated landmark time percentages and the median value will be based on this.
Confidence intervals for median values will use the Brookmeyer-Crowley method.
Survival outcomes between carcinoid tumors and pancreatic neuroendocrine tumor (PNET)s will be compared using a log-rank test.
|
From study registration to radiographic progression per RECIST v1.1 (investigator assessment), clinical progression, or death of any cause, assessed up to 1 year
|
Overall survival
Time Frame: Time from study registration to death of any cause, assessed up to 1 year
|
The distribution for survival times will be estimated using the method of Kaplan-Meier; associated landmark time percentages and the median value will be based on this.
Confidence intervals for median values will use the Brookmeyer-Crowley method.
Survival outcomes between carcinoid tumors and PNETs will be compared using a log-rank test.
|
Time from study registration to death of any cause, assessed up to 1 year
|
Incidence of adverse events
Time Frame: Up to 30 days
|
Safety will be evaluated by assessing the adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David B. Zhen, Fred Hutch/University of Washington Cancer Consortium
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Intestinal Diseases
- Pancreatic Diseases
- Neoplasms
- Stomach Neoplasms
- Pancreatic Neoplasms
- Neuroendocrine Tumors
- Intestinal Neoplasms
Other Study ID Numbers
- RG1004456
- NCI-2019-01490 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 9959 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
M.D. Anderson Cancer CenterTerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Roswell Park Cancer InstituteIpsenActive, not recruitingUnresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditionsUnited States
-
Jiangsu HengRui Medicine Co., Ltd.CompletedLocally Advanced or Metastatic and Unresectable HCCUnited States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
-
FutureGen Biopharmaceutical (Beijing) Co., LtdRecruitingLocally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
Shanghai Runshi Pharmaceutical Technology Co., LtdJilin Provincial Tumor HospitalRecruitingLocally Advanced Unresectable CarcinomaChina
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
Clinical Trials on Abemaciclib
-
Nader SanaiEli Lilly and Company; Barrow Neurological Institute; Ivy Brain Tumor CenterNot yet recruiting
-
University of ArizonaGeorge Washington UniversityRecruiting
-
Weill Medical College of Cornell UniversityEli Lilly and CompanyRecruitingBladder CancerUnited States
-
Memorial Sloan Kettering Cancer CenterEli Lilly and CompanyActive, not recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisCompleted
-
Medical College of WisconsinRecruitingSoft Tissue Sarcoma | Osteosarcoma | ChondrosarcomaUnited States
-
Eli Lilly and CompanyCompletedHealthyUnited States
-
Eli Lilly and CompanyCompleted
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
Nader SanaiEli Lilly and Company; Barrow Neurological Institute; Ivy Brain Tumor CenterRecruitingGlioma | Glioblastoma | GBMUnited States